Hexyl aminolevulinate

Drug Profile

Hexyl aminolevulinate

Alternative Names: 5-ALA hexylester; 5-ALA hexylesther; aminolevulinic acid hexyl ester; Cevira; Cysview; HAL-PDT; hexaminolevulinate; Hexvix; Hexvix PDT; hexyl 5-aminolevulinate; P 1206

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator PhotoCure
  • Developer Photocure
  • Class Amino acids; Antineoplastics; Esters; Levulinic acids; Oxidants; Small molecules
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Cervical intraepithelial neoplasia

Highest Development Phases

  • Marketed Bladder cancer
  • Phase II Cervical intraepithelial neoplasia
  • Discontinued Colorectal cancer

Most Recent Events

  • 15 Feb 2017 Photocure announces intention to submit sNDA to US FDA in 2017
  • 15 Feb 2017 Photocure completes enrolment in a phase III trial for Bladder cancer (Diagnosis) in USA (NCT02560584)
  • 17 Nov 2015 Launched for Bladder cancer (Diagnosis) in Canada (Intravesicular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top